NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 193 filers reported holding NEKTAR THERAPEUTICS in Q1 2023. The put-call ratio across all filers is 0.02 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $33,448 | -28.8% | 14,800 | 0.0% | 0.00% | -100.0% |
| Q3 2022 | $47,000 | -56.9% | 14,800 | -48.6% | 0.00% | -50.0% |
| Q2 2022 | $109,000 | -99.6% | 28,800 | -99.4% | 0.00% | -99.3% |
| Q1 2022 | $25,917,000 | -56.9% | 4,808,401 | +8.0% | 0.30% | -51.5% |
| Q4 2021 | $60,142,000 | -27.1% | 4,451,693 | -3.1% | 0.62% | -25.9% |
| Q3 2021 | $82,519,000 | +17.2% | 4,594,656 | +12.0% | 0.84% | +21.8% |
| Q2 2021 | $70,380,000 | -11.0% | 4,101,404 | +3.7% | 0.69% | -17.9% |
| Q1 2021 | $79,093,000 | +20.3% | 3,954,604 | +2.3% | 0.84% | +11.2% |
| Q4 2020 | $65,726,000 | +9.1% | 3,866,258 | +6.4% | 0.75% | -9.6% |
| Q3 2020 | $60,261,000 | -26.4% | 3,632,358 | +2.8% | 0.83% | -28.1% |
| Q2 2020 | $81,871,000 | +31.6% | 3,535,013 | +1.4% | 1.16% | -3.9% |
| Q1 2020 | $62,202,000 | -15.7% | 3,484,713 | +2.0% | 1.21% | +3.2% |
| Q4 2019 | $73,756,000 | +27.6% | 3,416,998 | +7.7% | 1.17% | +8.7% |
| Q3 2019 | $57,794,000 | -38.3% | 3,172,886 | +20.5% | 1.08% | -32.8% |
| Q2 2019 | $93,671,000 | +548.3% | 2,632,686 | +512.2% | 1.60% | +101.1% |
| Q1 2019 | $14,449,000 | +68.3% | 430,026 | +64.6% | 0.80% | +40.7% |
| Q4 2018 | $8,586,000 | +153.7% | 261,210 | +370.5% | 0.56% | +162.8% |
| Q3 2018 | $3,384,000 | +100.8% | 55,520 | +60.9% | 0.22% | +49.3% |
| Q2 2018 | $1,685,000 | -55.3% | 34,500 | -2.8% | 0.14% | -61.5% |
| Q1 2018 | $3,772,000 | -15.4% | 35,500 | -52.5% | 0.37% | -19.7% |
| Q4 2017 | $4,461,000 | +51.1% | 74,700 | -39.3% | 0.47% | +50.8% |
| Q3 2017 | $2,952,000 | +251.0% | 123,000 | +186.0% | 0.31% | +212.1% |
| Q2 2017 | $841,000 | -79.2% | 43,000 | -75.0% | 0.10% | -81.6% |
| Q1 2017 | $4,036,000 | +76.9% | 172,000 | -7.5% | 0.54% | +15.2% |
| Q4 2016 | $2,282,000 | -28.6% | 186,000 | 0.0% | 0.47% | -19.1% |
| Q3 2016 | $3,195,000 | +20.7% | 186,000 | 0.0% | 0.58% | +15.9% |
| Q2 2016 | $2,647,000 | -10.9% | 186,000 | -13.9% | 0.50% | -7.6% |
| Q1 2016 | $2,970,000 | – | 216,000 | – | 0.54% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rhenman & Partners Asset Management AB | 508,000 | $6,132,000 | 1.80% |
| Bodri Capital Management, LLC | 250,000 | $3,018,000 | 1.46% |
| Granahan Investment Management | 3,442,980 | $41,557,000 | 1.28% |
| TIRSCHWELL & LOEWY INC | 603,441 | $7,284,000 | 1.22% |
| NEA Management Company, LLC | 1,825,600 | $22,035,000 | 1.12% |
| Cormorant Asset Management, LP | 450,000 | $5,432,000 | 1.12% |
| HARVEY CAPITAL MANAGEMENT INC | 221,750 | $2,676,000 | 1.05% |
| Cheyne Capital Management (UK) LLP | 229,577 | $2,772,000 | 0.99% |
| Artal Group S.A. | 1,650,000 | $19,916,000 | 0.73% |
| FIC CAPITAL INC | 147,293 | $1,778,000 | 0.71% |